Irbesartan Aurovitas

Irbesartan, the active ingredient in Irbesartan Aurovitas, is an angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is used to manage high blood pressure and related cardiovascular conditions in adult patients.

GNH USA supplies Irbesartan Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the angiotensin II receptor blocker class and is employed in several cardiovascular and renal disease pathways. - Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and myocardial infarction. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: improves symptoms and decreases hospitalisation rates in patients with reduced ejection fraction.

Adverse reactions may occur with Irbesartan therapy.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache, often mild to moderate in intensity. - Fatigue or general weakness. - Elevated serum potassium levels. - Nasal congestion or upper respiratory discomfort.

Serious or Rare Side Effects: - Angioedema involving the face, lips, tongue or airway. - Acute kidney injury or significant rise in serum creatinine. - Severe hypotension leading to syncope. - Hepatic injury manifested by jaundice or elevated liver enzymes.

Before initiating Irbesartan, several safety considerations should be observed. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: check serum creatinine and eGFR periodically. - Serum potassium: monitor for hyperkalaemia, especially when combined with potassium‑sparing agents. - Pregnancy: discontinue if pregnancy is confirmed; the drug is contraindicated (Category D). - Hepatic impairment: use with caution and adjust therapy as needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase the risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - ACE inhibitors: concurrent use raises the chance of severe hypotension and hyperkalaemia. - NSAIDs (e.g., ibuprofen, naproxen): can impair renal function and blunt antihypertensive effect.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive response, requiring dose adjustment. - Lithium: increased lithium levels may lead to toxicity. - Cyclosporine or tacrolimus: may raise serum creatinine, necessitating renal monitoring.